TriSalus Life Sciences In... (TLSI)
| Bid | 4.5 |
| Market Cap | 179.43M |
| Revenue (ttm) | 29.43M |
| Net Income (ttm) | -30.06M |
| EPS (ttm) | -1.31 |
| PE Ratio (ttm) | -4.24 |
| Forward PE | -16.82 |
| Analyst | Buy |
| Ask | 5.7 |
| Volume | 47,559 |
| Avg. Volume (20D) | 51,345 |
| Open | 5.63 |
| Previous Close | 5.63 |
| Day's Range | 5.35 - 5.77 |
| 52-Week Range | 3.50 - 10.24 |
| Beta | 0.49 |
About TLSI
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular...
Analyst Forecast
According to 6 analyst ratings, the average rating for TLSI stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 97.84% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · seekingalpha.com
TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call TranscriptTriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Mary Szela - President &...
2 months ago · businesswire.com
TriSalus Life Sciences Announces Key Appointments to Board of DirectorsDENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative deliver...
